Drug intelligence / Profile preview

F7

Development stage: Preclinical
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

F7 is a specific cannabis extract fraction, identified as a phytocannabinoid, that demonstrates synergistic activity with the Poly(ADP-Ribose) Polymerase 1 (PARP1) inhibitor niraparib. This combination promotes apoptosis in ovarian cancer cells. F7's mechanism of action involves modulating multiple genetic pathways, including Hippo/Wnt, TGF-β/Activin, and MAPK signaling pathways. This modulation leads to several cellular effects such as cell cycle arrest, induction of endoplasmic reticulum (ER) stress, inhibition of cell migration, reduction in the percentage of aldehyde dehydrogenase (ALDH) positive cells, and enhanced PARP1 cleavage.

Other names: cannabis extract fraction

Targets

TRPV2 (Transient receptor potential cation channel subfamily V member 2)CB (Cannabinoid receptors)

Beyond the preview

Go deeper on F7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F7.

Explore the full profile